Welcome to our dedicated page for Kraig Biocraft Laboratories In SEC filings (Ticker: KBLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kraig Biocraft Laboratories SEC filings document material-event disclosures for an OTCQB-traded recombinant spider silk company. The filing record includes Form 8-K reporting tied to public-company events and corporate communications, including disclosure of media coverage related to the company’s spider silk technology. These filings identify the registrant, its Wyoming corporate status, reporting file number, and current public-company context.
Kraig Biocraft Laboratories, Inc. filed Post-Effective Amendment No. 3 to its Form S-1 to register up to 207,787,193 shares of Common Stock for resale by YA II PN, Ltd. under a Standby Equity Purchase Agreement (SEPA). The SEPA commits up to $10,000,000 of purchases; the company has sold 51,443,697 shares under the SEPA for aggregate gross proceeds of $4,524,430. The filing states the Company may, at its discretion, direct additional sales to the investor and that resale by the Selling Stockholder will not provide proceeds to the Company. The independent auditor included a going concern explanatory paragraph for fiscal years ended December 31, 2025 and 2024. Shares outstanding were 1,103,871,733 as of April 20, 2026; CEO Kim Thompson beneficially owns approximately 14.07% and holds Series A Preferred voting control. The prospectus describes risk factors, the SEPA mechanics (including a 4.99% beneficial ownership cap for the investor), and potential dilution scenarios.
Kraig Biocraft Laboratories’ annual report shows it is still pre-revenue and recorded a net loss of $3,623,353 for the year ended December 31, 2025, slightly higher than the prior year’s loss of $3,398,939. The auditor’s report includes a going concern warning due to recurring losses, a stockholders’ deficit of $7,998,958, and an accumulated deficit of $56,709,072. At year-end, the company held cash and cash equivalents of $1,790,236 against current liabilities of $10,445,245, resulting in a working capital deficit of $8,576,604. To bolster liquidity, Kraig entered a $10 million Standby Equity Purchase Agreement, allowing it to sell common shares at its discretion. The business continues to focus on developing recombinant spider silk fibers via genetically engineered silkworms, with production centered in Vietnam and ongoing R&D aimed at improved fiber performance and silkworm robustness.
Kraig Biocraft Laboratories, Inc. disclosed that it has been featured in a cover article of the March 2026 issue of National Geographic. The company notes that this March 2026 issue is currently available only in select markets and is expected to be distributed nationally in the coming weeks.
Kraig Biocraft Laboratories (KBLB) reported Q3 results with revenue of $0 and a net loss of $1,509,566 for the quarter; the nine‑month net loss was $2,835,732. Operating expenses were $1,433,888 in Q3 and $2,652,125 year‑to‑date.
As of September 30, 2025, the Company had cash of $1,565,692, a working capital deficiency of $8,544,784, and a stockholders’ deficit of $7,956,077. Management disclosed that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Financing activity included $1,925,702 raised under a Standby Equity Purchase Agreement and common shares issued for services valued at $834,600. The Company sold 111 ounces of gold year‑to‑date for $369,992 in proceeds, recognizing a $160,896 realized gain; remaining gold was carried at $494,478. Related‑party note payable was $1,567,000 with $426,589 in year‑to‑date interest expense. Accounts payable and accrued expenses – related party were $8,004,099. Class A shares outstanding were 1,080,852,130 as of November 12, 2025; 1,076,244,777 were outstanding as of September 30, 2025.